Phenotype-Oriented Ablation of Oligometastatic Cancer with Single Dose Radiation Therapy.
The current oligometastatic (OM) model postulates that the disease evolves dynamically with sequential emergence of OM (SOM) lesions requiring successive rounds of SOM ablation to afford tumor cure. The present phase 2 study explores the ablative efficacy of 24 Gy single-dose radiation therapy (SDRT), its feasibility in diverse OM settings, and the impact of radioablation on polymetastatic (PM) dissemination. One hundred seventy-five consecutive patients with 566 OM or SOM lesions underwent periodic positron emission tomography/computed tomography (PET/CT) imaging to stage the disease before treatment, determine tumor response, and monitor timing of PM conversion after SDRT. When 24 Gy SDRT was restricted by dose or volume constraints of serial normal organs, radioablation was diverted to a nontoxic 3×9 Gy SBRT schedule. SOM/SOMA occurred in 42% of the patients, and 24 Gy SDRT was feasible in 76% of the lesions. Despite 92% actuarial 5-year OM ablation by 24 Gy SDRT, respective PM-free survival (PMFS) was 26%, indicating PM conversion dominates over effective OM radioablation in many patients. Multivariate analysis of OM metrics derived from staging PET/CT scanning before first treatment predicted PMFS outcome after SDRT. Bivariate analysis of dichotomized high versus low baseline metric combinations of CT-derived tumor load (cutoff at 14.8 cm3) and PET-derived metabolic SUVmax (cutoff at 6.5) yielded a 3-tiered PMFS categorization of 89%, 58% and 17% actuarial 5-year PMFS in categories 1, 2, and 3, respectively (P < .001), defining OM disease as a syndrome of diverse clinical and prognostic phenotypes. Long-term risk of PM dissemination, predicted by preablation PET/CT staging, provides guidelines for phenotype-oriented OM therapy. In categories 1 and 2, radioablation should be a primary therapeutic element when pursuing tumor cure, whereas in the PM-prone category 3, radioablation should be a component of multimodal trials addressing primarily the risk of PM dissemination. PET/CT baseline staging also provides a platform for discovery of pharmacologically accessible PM drivers as targets for new phenotype-oriented treatment protocols.